USSTOCK.TODAY
Weekend. Closed Log in Sign up

Vertex Pharmaceuticals Chairman: Strategic Focus Achieves Over 70% Clinical Success Rate

Fortune · ·by G4L

VERX
VERX Vertex Inc
$17.23 +0.29%
View chart & analysis →
  1. 1Vertex Pharmaceuticals Chairman Jeffrey Leiden shared how the company increased its clinical trial success rate to over 70%.
  2. 2Vertex Pharmaceuticals recorded an R&D success rate of over 83% through Phase 2 proof-of-concept in six diseases.
  3. 3Vertex Pharmaceuticals developed the first FDA-approved human gene-editing therapy in collaboration with CRISPR Therapeutics.

So what's the key point?

Vertex Pharmaceuticals is having very successful research and development. It showed a success rate of over 83 percent in studies for six diseases.

Source Fortune · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →